Related Experiment Video

Updated: Mar 8, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.5K

Analysis of MMP-7 and TIMP-2 gene polymorphisms in coronary artery disease and myocardial infarction: A Turkish

Ebru Alp1, Akin Yilmaz2, Murat Tulmac3

  • 1Department of Medical Biology, Faculty of Medicine, Giresun University, Giresun, Turkey.

The Kaohsiung Journal of Medical Sciences
|February 1, 2017
PubMed

Insights

Genetic variations in matrix metalloproteinase-7 (MMP-7) and tissue inhibitors of metalloproteinase-2 (TIMP-2) were analyzed for their association with coronary artery disease (CAD) and myocardial infarction (MI). The MMP-7 C-153T polymorphism showed a significant association with MI development in CAD patients.

Area of Science:

  • Cardiovascular Genetics
  • Molecular Biology
  • Biochemistry

Background:

  • Matrix metalloproteinase (MMP) and tissue inhibitors of metalloproteinase (TIMP) play crucial roles in cardiac tissue remodeling.
  • Previous research has explored associations between specific MMP-7 and TIMP-2 gene polymorphisms and various diseases.
  • The link between these polymorphisms and coronary artery disease (CAD) remains under-investigated.

Purpose of the Study:

  • To investigate the association between specific polymorphisms in MMP-7 and TIMP-2 genes and the risk of CAD and myocardial infarction (MI).
  • To analyze MMP-7 A-181G (rs11568818), C-153T (rs11568819), C-115T (rs17886546), and TIMP-2 G-418C (rs8179090) polymorphisms in relation to CAD and MI.

Main Methods:

  • Genotyping of MMP-7 and TIMP-2 polymorphisms was performed using polymerase chain reaction-restriction fragment length polymorphism and automated direct sequencing.
  • DNA was extracted from whole blood samples of 122 CAD patients and 132 control individuals from a Turkish population.
  • Statistical analysis was conducted to compare genotype and allele frequencies between patient and control groups.

Main Results:

  • No significant associations were found between MMP-7 A-181G, C-115T, and TIMP-2 G-418C polymorphisms and CAD or MI.
  • While genotype frequencies of the MMP-7 C-153T polymorphism did not differ significantly between MI and control groups, allele frequencies showed a significant difference.
  • This study is the first to report a potential relationship between the MMP-7 C-153T polymorphism and MI development in CAD patients.

Conclusions:

  • The MMP-7 C-153T polymorphism may be associated with an increased risk of myocardial infarction in patients with coronary artery disease.
  • Other studied MMP-7 and TIMP-2 polymorphisms (A-181G, C-115T, G-418C) do not appear to be significantly linked to CAD or MI in this population.
  • Further validation in diverse ethnic populations is necessary to confirm these findings and elucidate the genetic factors contributing to CAD development.
Keywords:
Coronary artery diseaseMMP-7Myocardial infarctionPolymorphismTIMP-2

More Related Videos

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.9K
Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts08:51

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts

Published on: September 20, 2024

2.2K

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
670
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
60
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
19.2K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
56
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
76
Role of Matrix Metalloproteases in Degradation of ECM01:23

Role of Matrix Metalloproteases in Degradation of ECM

Matrix metalloproteases (MMPs) are enzymes involved in the hydrolysis of proteins and glycoproteins of the extracellular matrix. MMPs are essential for the migration and proliferation of cells through the dense matrix network, throughout embryonic development, and throughout morphogenesis. The first MMP activity discovered was a collagenase in a tadpole's tail undergoing metamorphosis. The active collagen deposition and modifications lead to the morphogenesis of tadpoles into the adult...
3.6K